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Abstract 
Background & Aims: Idiopathic chronic pancreatitis (ICP) is the second most common subtype 
of CP. In 1994, researchers reported the bimodal age at onset of ICP symptoms: early-onset ICP 
(EO-ICP; median age, 19.2 years) and late-onset ICP (LO-ICP; median age, 56.2 years). Ages of 
onset and clinical features of ICP differed from those of alcohol-related CP (ACP). However, 
variants in PRSS1 had not yet been associated with ICP. We reexamined ag s of onset of ICP in 
a large, North American cohort of patients, and investigated the effects of genetic factors and 
alcohol use in patients with EO-ICP, LO-ICP, or ACP. 
Methods: We performed a cross-sectional analysis of patients with CP of European ancestry 
enrolled in the North American Pancreatitis Study 2 studies, a prospective study of 1195 patients 
with CP from 26 centers in the United States from August 2000 through December 2014. We 
compared age at onset of symptoms for 130 patients with CP who were lifetime abstainers from 
alcohol (61 patients with early onset and 69 patients with late onset), 308 light to moderate 
alcohol drinkers with CP, and 225 patients with ACP and heavy to very heavy alcohol use. DNA 
from available patients was analyzed for variants associated with CP in SPINK1, CFTR, and 
CTRC. The Kruskal-Wallis test was used to compare continuous variables across groups and 
based on genetic variants. 
Results: Median ages at onset of symptoms were 20 years for patients with EO-ICP and no 
alcohol use, 58 years for patients with LO-ICP and no alcohol use, 47 years for light to moderate 
alcohol drinkers with CP, and 44 years for patients wi h ACP. A higher proportion of patients 
with EO-ICP had constant pain (65%) than patients wi h LO-ICP (31%) (P=.04). A higher 
proportion of patients with ACP had pseudocysts (43%) than patients with EO-ICP (11%) 
(P=.001). A higher proportion of patients with EO-ICP had pathogenic variants in SPINK1, 
CFTR, or CTRC (49%) than patients with LO-ICP (23%), light to moderate alcohol drinking 
with CP (26%), or ACP (23%) (P=.001). Among patients with variants in SPINK1, those with 
EO-ICP had onset of symptoms at a median age of 12 years, and light to moderate alcohol 
drinkers with CP had an age at onset of 24 years. Among patients with variants in CFTR, light to 
moderate alcohol drinkers had an age at onset of symptoms of 41 years, but this variant did not 
affect age at onset of EO-ICP or ACP. 
Conclusions: We confirmed previously reported ages at onset of symptoms for EO-ICP and LO-
ICP in a North American cohort. We found differences in clinical features among patients with 
EO-ICP, LO-ICP, and ACP. Almost half of patients with EO-ICP have genetic variants 
associated with CP, compared to about one-quarter of patients with LO-CP or ACP. Genetic 
variants affect ages at onset of symptoms in some groups. 
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Introduction 
Chronic pancreatitis (CP), a syndrome of pancreatic inflammation and dysfunction, is a 
worldwide problem. While earlier studies suggested that the vast majority of patients were heavy 
alcohol users and nearly all men,1-4 there is growing recognition of other risk factors, such as 
genetic susceptibility, smoking, and autoimmunity.5,6 Idiopathic CP (ICP) is the second most 
common form of CP.  
In 1994, Layer et al7 reported a retrospective analysis of ICP patients seen at Mayo Clinic 
between 1976 and 1982, with prospective follow-up through 1985. They identified 66 patients 
who were abstinent from alcohol and had no other idnt fiable causes of CP. They reported a 
bimodal age at onset of disease, early-onset ICP (EO-ICP) and late-onset ICP (LO-ICP), with the 
distinction set as an age at onset of 35 years or younger or older than 35 years, and compared 
these patient groups to 249 patients with alcohol-related CP (ACP). ACP was defined by 
consumption of 50 g or more of alcohol per day (≥4 drinks/day). Patients with alcohol 
consumption of less than 50 g per day were excluded from the study. In the 2 ICP groups, the 
median age at onset was 19.2 and 56.2 years, respectively, while the median age at onset of ACP 
was 43.9 years. This study suggested an equal distribution among the sexes in both EO-ICP and 
LO-ICP, while ACP patients were more frequently men. Patients with EO-ICP had more pain, 
but slower onset of calcifications and pancreatic dysfunction than LO-ICP. Conversely, nearly 
half the patients with LO-ICP were without pain. In a follow-up evaluation, the authors reported 
that intake of alcohol, even smaller amounts (ie, low to moderate alcohol consumption group) 
resulted in earlier onset of disease, more frequent pai , and calcifications.8 To our knowledge, 
these results have not been validated in the United S ates. 
Since 1994, the etiologic spectrum of CP has markedly expanded. In 1996, we reported 
mutations in the cationic trypsinogen gene (PRSS1) to be the cause of hereditary pancreatitis,9 
opening the door to a broader view of pancreatitis to nclude genetic risk and etiologies.10-15 The 
study by Layer et al7 was limited to a “family history of pancreatitis” as an exclusion factor for 
inherited disease, and therefore, was not able to sparate patients with PRSS1 mutations without 
suggestive family history or complex genetic disorders associated with sequence variants in 
CFTR, SPINK1, and CTRC in their ICP group. Furthermore, smoking is now recognized as an 
important risk factor for pancreatitis with importan  interactions with alcohol use,5,6 and 
autoimmune pancreatitis is recognized as a form of CP.16,17  
The North American Pancreatitis Study 2 (NAPS2) provides an ideal cohort to reexamine 
the findings by Layer et al.7 Given our current understanding, we hypothesized that major 
pathogenic genetic variants would be more prevalent in patients with EO-ICP when compared 
with LO-ICP and ACP, and may explain a bimodal distribution of ICP.  
 
Materials and Methods 
North American Pancreatitis Studies 
NAPS2 is a set of 3 studies (original NAPS2, NAPS2 continuation and validation study, 
and NAPS2 Ancillary Study) that prospectively enrolled 1,195 patients with CP from 26 centers 
in the United States from August 2000 to December 2014.18-20 The diagnosis of CP was based on 
definitive changes on abdominal imaging studies, specifically endoscopic retrograde 
cholangiopancreatography, contrast-enhanced computed tomography, magnetic resonance 
imaging, endoscopic ultrasound, or histology as previously described. On endoscopic ultrasound, 
at least 5 parenchymal or ductal changes or the presenc  of calcifications were required. Detailed 
information was collected from patients and their enrolling physician using 2 case report forms. 
All patients provided a written informed consent prior to any study procedures. Study patients 
also provided a blood sample for research purposes. The studies were approved by the 
institutional review board at each participating inst tution. Detailed methodology of NAPS2 
studies has been published previously.18-20 All authors had access to the study data and have 
reviewed and approved the final manuscript. 
 
Study Cohort 
To make the study cohort comparable to the Layer et al study,7 of the 1,195 CP patients 
in the NAPS2 cohort, we sequentially excluded patients as shown in Figure 1. Initially, we 
excluded those who self-identified themselves as non-European ancestry and those for whom 
ancestry was unknown. Among CP patients of European ancestry, we excluded those with 
PRSS1 variants associated with hereditary pancreatitis (ie, p.N29I, p.R122H) on post hoc genetic 
testing (done for research after enrollment) and those for whom results were unknown. We 
further excluded patients for whom the enrolling physician identified another etiology for CP, 
such as autoimmune, obstructive, or hyperlipidemia, those who reported a family history of 
hereditary pancreatitis, those with incomplete drinking history, and those in whom genetic 
testing for CFTR, SPINK1, and CTRC was incomplete or unsuccessful.  
 
Patient Classification 
Patients who self-reported to be lifetime abstainers of alcohol and had onset of 
pancreatitis symptoms at 35 years of age or younger were classified as having EO-ICP, while 
those with onset of pancreatitis symptoms after 35 were classified as having LO-ICP, as in the 
Layer et al study.7 For self-reported ever drinkers, we used information on drinking during the 
maximum lifetime drinking period to classify patients into those with alcohol consumption of 4 
drinks or fewer per day (light to moderate drinking with CP) and more than 4 drinks per day 
(ACP), similar to the study by Layer et al.7  
 
Genetic Testing 
Post hoc analysis for known genetic mutations in PRSS1, CFTR, SPINK1, and CTRC 
genes was performed in all NAPS2 patients for whom an adequate amount of DNA sample was 
available. Detailed methods have been described previously.21-24 
 
Clinical Data 
Relevant data for this study were obtained from case report forms completed by the 
patients with assistance from the site coordinator nd the enrolling physician as needed. This 
information included demographics, self-reported alcohol and smoking history, physician-
defined etiology, age at first symptoms of pancreatitis, history of acute pancreatitis (AP), pain 
symptoms and disability, exocrine insufficiency, diabetes mellitus, morphologic changes in the 
pancreas, and medical, endoscopic, and surgical treatments received prior to enrollment. Data on 
pain and narcotic use were limited to the NAPS2 continuation and validation study as this study 
specifically asked patients to report presence of pain in the year preceding enrollment and 
physicians to report on patients’ patterns of pain medication use. Smoking status was classified 




For discrete variables, the counts and proportions within each etiology group are 
presented as descriptive statistics. For continuous variables, the median and interquartile range 
(IQR) are presented as descriptive statistics for each etiology group. The Pearson χ2 test with 
continuity correction was used to compare discrete variables across all 4 etiology groups and 
between the EO-ICP and LO-ICP groups. The Kruskal-Wlis test was used to compare 
continuous variables across all 4 etiology groups, between the EO-ICP and LO-ICP groups, and 




The final sample size for this study was 663 patients with CP. Of these, 130 (19.6%) 
were lifetime alcohol abstainers placed in 1 of the 2 ICP groups, 308 (46.5%) were light to 
moderate alcohol drinkers with CP, and 225 (33.9%) were heavy to very heavy alcohol drinkers 
placed in the ACP group (Figure 1). Among the 130 patients with ICP, 61 (46.9%) had EO-ICP, 
and 69 (53.1%) had LO-ICP. 
 
Demographics, History of Smoking, and Age at Onset of Symptoms 
  The age at onset of pancreatitis symptoms and pancre titis diagnosis in patients with ICP 
followed a bimodal distribution (Table 1, Figure 2). Median (IQR) age at onset was 20 (12-27) 
years and 58 (46-67) years in patients with EO-ICP and LO-ICP, respectively. In light to 
moderate alcohol drinkers with CP, the median (IQR) age at onset of symptoms was 47 (35-61) 
years and in those with ACP it was 44 (36-52) years (Table 1).  
Table 1 shows the distribution of sex significantly differed between patient groups. 
Patients with EO-ICP or LO-ICP were predominantly women (62% and 81%, respectively), light 
to moderate alcohol drinkers with CP were evenly spit (53% men), and those with ACP were 
predominantly men (73%). Patients with LO-ICP were significantly more likely to be women 
when compared with EO-ICP (Table 1). Almost three-quarters of patients with ACP and 41% of 
light to moderate alcohol drinkers with CP were current smokers, which was significantly higher 
than those with ICP. Similarly, over half of those with ACP and 42% of light to moderate 
alcohol drinkers with CP smoked 1 or more packs per day, while patients with ICP smoked 
significantly fewer packs per day. Smoking habits were similar among patients with EO-ICP and 
LO-ICP. There was no difference in body mass index b tween the ICP groups. 
 
AP, Pain Frequency and Severity, and Disability 
Over 50% of patients in each of the groups had at least 1 attack of AP during their 
clinical course. The highest prevalence of AP was in the EO-ICP group, which was significantly 
higher than in the LO-ICP group (Table 1).  
Patient pain characteristics, including temporal nature and pain severity, are shown in 
Table 2. Almost all patients with EO-ICP reported pain (96%), which was significantly more 
than patients with LO-ICP (69%; P=.04). The majority of light to moderate alcohol drinkers with 
CP and those with ACP also reported pain, though at a lower frequency than patients with EO-
ICP. The temporal nature and severity of pain was mo tly similar among patients with EO-ICP, 
with description of constant and severe pain being more frequent than in patients with LO-ICP.  
  Many patients in all 4 groups reported narcotic use to treat pain, either intermittently or 
on a constant basis (Table 2). While approximately 50% of patients with EO-ICP or ACP were 
on constant narcotics, only about 25% of patients wi h LO-ICP or light to moderate alcohol 
drinkers with CP required constant narcotic use. Overall, about 1 in 5 patients reported disability 
due to CP (140/663 [21.1%], Table 1). The prevalence of disability was the highest among 
patients with EO-ICP when compared to other groups.  
 
Sequelae of CP and Treatment  
The sequelae of CP and treatments are presented in Table 1. No major differences were 
detected in the rates of endocrine and exocrine insuff ciency between groups. Although presence 
of pancreatic calcifications was not statistically different between groups, calcifications were 
most frequent in patients with ACP (62%) and least frequent in those with EO-ICP (46%). 
Prevalence of pseudocysts was significantly higher in patients with ACP compared to the other 
groups (P<.001). Medical treatment with pancreatic enzyme replacement therapy was more 
common in the EO-ICP group (85%) when compared withthe other 3 groups, where it was used 
in about two-thirds of patients. Just over 50% of patients with EO-ICP underwent pancreatic 
sphincterotomy or pancreatic duct stent placement, which was more than the other 3 groups. 
There was no difference between performances of surgical interventions between the groups.  
 
Genetic Analysis  
We evaluated the prevalence of pathogenic variants n CFTR, SPINK1, and CTRC genes 
previously associated with pancreatitis in the 4 patient groups and their effect on age at symptom 
onset (Tables 3 and 4). Nearly 50% of patients withEO-ICP carried a pathogenic variant 
associated with at least 1 of these 3 genes, which was significantly greater than the other 3 
groups, where variants were observed in about 25% of patients each. Interestingly, presence of 
mutations accelerated the clinical presentation with earlier onset of symptoms, especially in light 
to moderate alcohol drinkers with CP (Table 4). In subgroup analyses, the effects of having a 
SPINK1 mutation significantly accelerated the onset of symptoms in the EO-ICP group from 22 
years to 12 years (P=.004) and in the light to moderate alcohol drinkers with CP group from 50 
years to 24 years (P<.001). Having a CFTR mutation accelerated the age at onset of symptoms 
for light to moderate alcohol drinkers with CP from 50 years to 41 years (P=.03), but did not 
affect age at onset in the other 3 groups.  
 
Discussion 
The NAPS2 cohort allows for the reevaluation of prior descriptive studies of cohorts of 
CP in light of newer insights into etiopathogenesis, including genetics. We confirmed the 
existence of 2 types of ICP, EO-ICP and LO-ICP, with a nearly identical bimodal age 
distribution to the previously published series.7 We also confirmed several other clinical features 
that characterize patients with EO-ICP and LO-ICP, suggesting that they represent 2 distinct 
populations of patients with overlapping features. We found that almost half of patients with EO-
ICP had underlying genetic variations, suggesting a potential genetic etiology for these 
previously described ICP cases. Furthermore, we highlighted the possibility of a gene-
environment interaction between the presence of genetic variations and alcohol consumption.  
Layer et al7 recognized the existence of rare patients with hereditary pancreatitis, but had 
to rely on a strong family history. In 1996, PRSS1 p.R122H and p.N29I were discovered as 
causes of hereditary pancreatitis, allowing for genetic testing of individual patients.9 Since then, 
numerous genetic factors associated with pancreatitis have been discovered and divided into 
pathogenic variants (ie, sufficient to cause a Mendelian disorder) and risk factors (ie, part of 
multi-risk factor complexes).15 In the present study, we focused on pathogenic varants in PRSS1, 
CFTR, SPINK1, and CTRC (excluding the CTRC p.G60G risk haplotype). Our findings highlight 
the significance of genetic variations on clinical presentation, especially in patients with EO-ICP, 
and in their interaction with alcohol use, most notably lowering the age at disease onset in light 
to moderate alcohol drinkers with CP. It is likely that patients with EO-ICP in whom no 
mutations were identified may harbor currently unknow  mutations or complex risk factor 
signatures in multiple genes currently under investigation.  
Patients with EO-ICP were more likely to have had episodes of AP than those with LO-
ICP, and had far more constant abdominal pain. These results are strikingly similar to Layer et 
al,7 where 100% of patients with EO-ICP reported pain. As in their LO-ICP group, we found that 
LO-ICP was a painless disease in approximately 30% of patients.7 Pain was substantial enough 
in all groups to necessitate narcotic medication use and lead to disability. In our study, EO-ICP 
and LO-ICP had similar rates of endocrine and exocrine insufficiency, in agreement with the 
previous study.7 Calcifications were more frequently found in patien s with ACP than with EO-
ICP, but not with statistical significance found by Layer et al.7 Calcifications were seen in almost 
half of the EO-ICP group (46%) in our study; this prevalence is different from the findings 
reported by Layer et al,7 where none of the 25 patients with EO-ICP had calcifications at 
presentation. The reason for a higher prevalence in our study is likely related to recording this 
observation at the time of study enrollment rather an at the time of symptom onset; most 
patients were enrolled several years after symptom onset. It may also be related to improvements 
in imaging technology now compared to over 2 decades ago. It is also notable that over 50% of 
patients with EO-ICP underwent sphincterotomies and pancreatic duct stent placements, much 
higher than in the other 3 groups. If genetic variants are likely to contribute to these younger 
patients having CP, the effectiveness of anatomic-based, endoscopic treatments deserves further 
study.  
Our classification of ICP mimics that of Layer et al7 in that all equivocal or uncertain 
diagnoses were excluded; however, important differences exist. We now recognize smoking as a 
common risk factor for CP and its notable interactions with alcohol use.5,6 In addition, we now 
recognize genetic etiologies as common causes of CP in younger patients.20 Although 
uncommon, patients suspected of having autoimmune pa creatitis were excluded from the 
current study and may have been included in the Layr et al study7 as it was not defined until 
2001.16  
Although EO-ICP and LO-ICP were defined more than 2 decades ago,7 this observation 
has not been formally replicated. A strength of NAPS2 is that it is a multicenter study providing 
a sampling of pancreatitis cases from referral centers throughout the United States. It also has the 
advantage of a much larger number of patients, so that sampling bias and random chance are less 
likely reasons for these observations. In addition, the NAPS2 patients were prospectively 
enrolled using improved diagnostic equipment that ws not available in the 1980s.  
One limitation of our study was that it was a cross-sectional cohort study, not allowing 
for longitudinal follow-up of patients. Thus, important long-term clinical outcomes, such as 
endocrine and exocrine insufficiency and changes in abdominal pain, could not be determined.  
In summary, our results confirm a bimodal distributon of ICP and demonstrate that a 
subset of these is likely related to an underlying genetic variation. Future studies using more 
advanced genetic analysis may further reduce the number of patients with truly idiopathic 
disease and better characterize the long-term course of these patients. 
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Legends 
Figure 1: Study Population Flow Chart. ACP indicates alcohol-related chronic pancreatitis; CP, 
chronic pancreatitis; EO-ICP, early-onset idiopathic chronic pancreatitis; LO-ICP, late-onset 
idiopathic chronic pancreatitis. 
Figure 2. Distribution of Age at Onset of Pancreatitis Symptoms. A, Patients with early-onset 
idiopathic chronic pancreatitis. B, Patients with late-onset idiopathic chronic pancreatitis. C, 
Light to moderate alcohol drinkers with chronic pancreatitis. D, Patients with alcohol-related 
chronic pancreatitis. 
  






Light to Moderate 







(EO-ICP vs LO-ICP) 
Sex, male , No. (%) 23 (38) 13 (19) 164 (53) 165 (73) <.001 .02 
Age at symptom onset, median, 
(IQR) 
20 (12-27) 58 (46-67) 47 (35-61) 44 (36-52) <.001 <.001 
Age at diagnosis, median (IQR) 26.5 (18-37) 60 (48-68) 52 (40-63) 47 (41-55) <.001 <.001 
Age at enrollment, median (IQR) 30.1 (20.8-40.0) 64.3 (52.1-70.9) 54.4 (42.4-65.6) 50.8 (44.0-57.4) <.001 <.001 
BMI, current, median (IQR) 25.0 (20.6-28.7) 25.8 (22.4-29.1) 24.2 (21.4-27.4) 23.4 (20.6-26.2) .003 .19 
BMI, maximum, median (IQR) 29.5 (25.1-36.5) 31.0 (27.8-33.5) 28.4 (25.5-32.7) 29.1 (25.0-32.8) .05 .23 
History of smoking, No. (%)a     <.001 .23 
Never 40/60 (67) 39 (57) 75/307 (24) 15 (7)   
Past 4/60 (7) 11 (16) 106/307 (35) 44 (20)   
Current 16/60 (27) 19 (28) 126/307 (41) 166 (74)   
Smoked ≥1 pack/day, No. (%) 7/57 (12) 9/62 (15) 126/302 (42) 127/221 (57) <.001 .82 
History of AP, No. (%)b 48/61 (79) 37/66 (56) 192/295 (65) 141/207 (68) .04 .02 
Disability due to CP, No. (%) 18 (30) 11 (16) 51 (17) 60 (27) .02 .10 
Calcifications, No. (%) 28 (46) 35 (51) 165 (54) 140 (62) .09 .71 
Pseudocysts, No. (%) 7 (11) 19 (28) 73 (24) 96 (43) <.001 .04 
Endocrine insufficiency, No. (%) 18 (30) 19 (28) 80 (26) 67 (30) .85 .96 
Exocrine insufficiency, No. (%) 18 (30) 25 (36) 108 (35) 82 (36) .86 .53 
PERT, No. (%) 52 (85) 46 (67) 205 (67) 148 (66) .04 .02 
Antioxidant vitamins, No. (%) 21 (34) 20 (29) 109/307 (36) 94 (42) .27 .63 
Pancreatic sphincterotomy, No. (%)c 14/26 (54) 10/26 (38) 58/154 (38) 32/133 (24) .02 .40 
Pancreatic duct stent, No. (%) 31 (51) 24 (35) 100 (32) 63 (28) .016 .10 
Pancreatic duct stone removal, No. (%) 6 (10) 4 (6) 41 (13) 30 (13) .45 .59 
Drainage operations, No. (%) 4 (7) 5 (7) 22 (7) 17 (8) ≥.99 ≥.99 
Partial or complete pancreatectomy, 
No. (%) 
10 (16) 15 (22) 53 (17) 41 (18) .91 .58 
Abbreviations: ACP, alcohol-related chronic pancreatitis; AP, acute pancreatitis; BMI, body mass index; CP, chronic pancreatitis; EO-ICP, early-onset idiopathic 
chronic pancreatitis; IQR, interquartile range; LO-ICP, late-onset idiopathic chronic pancreatitis; PERT, pancreatic enzyme replacement therapy; Q1, first 
quartile; Q3, third quartile. 
a Smoking data not reported for all patients. 
b AP status was never or unclear in remaining patient.  
c Only includes the North American Pancreatitis Studies continuation and validation (NAPS2-CV) study participants.  






Light to Moderate 







(EO-ICP vs LO-ICP) 
Pain pattern, No. (%)       
None 1 (4) 8 (31) 27 (18) 19 (14) .10 .04 
Intermittent 8 (31) 10 (38) 53 (34) 34 (26)   
Constant 17 (65) 8 (31) 74 (48) 80 (60)   
Pain severity, No. (%)       
None 1 (4) 8 (31) 27 (18) 19 (14) .07 .08 
Moderate 5 (19) 5 (19) 31 (20) 13 (10)   
Severe 20 (77) 13 (50) 96 (62) 101 (76)   
Pain medication, No. (%)       
None 5 (19) 11 (42) 65 (42) 33 (25) .01 .27 
Nonnarcotics 0 (0) 2 (8) 13 (8) 7 (5)   
Intermittent narcotics 8 (31) 7 (27) 37 (24) 29 (22)   
Constant narcotics 13 (50) 6 (23) 39 (25) 64 (48)   
Abbreviations: ACP, alcohol-related chronic pancreatitis; CP, chronic pancreatitis; EO-ICP, early-onset idiopathic chronic 
pancreatitis; LO-ICP, late-onset idiopathic chronic pancreatitis. 
a Data shown only from the North American Pancreatitis Studies continuation and validation (NAPS2-CV) study.  






Light to Moderate 







(EO-ICP vs LO-ICP) 
Any, No. (%) 30 (49) 16 (23) 79 (26) 51 (23) <.001 .004 
SPINK1, No. (%) 15 (24) 6 (9) 22 (7) 21 (9) <.003 .03 
CTRC, No. (%) 2 (3) 2 (3) 3 (1) 3 (1) .83 ≥.99 
CFTR, No. (%) 22 (36) 10 (15) 59 (19) 30 (13) .001 .008 
Abbreviations: ACP, alcohol-related chronic pancreatitis; CP, chronic pancreatitis; EO-ICP, early-onset idiopathic chronic 
pancreatitis; LO-ICP, late-onset idiopathic chronic pancreatitis. 
  







Light to Moderate 
Drinking with CP (n=308) 
ACP 
(n=225) 
Any, y, median (IQR)      
Yes 19.5 (8-23) 54.5 (45.5-67) 39 (25-52)a 44 (36-49) 
No 20 (16-29) 58 (47-67) 51 (40-63) 44 (36-53) 
SPINK1, y, median (IQR)     
Yes 12 (8-20) 54 (45-67) 24 (20-36)a 39 (28-44) 
No 22 (16.5-29)b 58 (46-67) 50 (38-62) 45 (36-52) 
CTRC, y, median (IQR)     
Yes 15.5 (4-27) 51.5 (42-61) 42 (39-45) 40 (39-48) 
No 20 (12-27) 58 (46-67) 47 (35-61) 44 (36-52) 
CFTR, y, median (IQR)     
Yes 21 (8-27) 47 (45-67) 41 (28-55)c 46.5 (41-51) 
No 19 (13-27) 59 (47-67) 50 (37-62) 43.5 (35.5-52) 
Abbreviations: ACP, alcohol-related chronic pancreatitis; CP, chronic pancreatitis; EO-ICP, early-onset idiopathic chronic 






What You Need to Know 
Background: Studies are needed to reexamine ages at onset of idiopathic chronic pancreatitis 
(ICP) in a modern, North American cohort of patients, as well as the effects of genetic factors 
and alcohol use in patients with early-onset, late-onset, and alcohol-related CP. 
Findings: We confirmed previously reported median at onset of symptoms for early-onset (20 
years) and late-onset (58 years) ICP in a North American cohort. We found differences in 
clinical and genetic features among patients with early-onset, late-onset, and alcohol-related CP.  
Implications for patient care: Early-onset, late-onset, and alcohol-related CP have distinct 
clinical and genetic features; these groups of patients should be managed differently.  
